Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II, double-blind, placebo-controlled study assessing the safety and efficacy of AVX-012 ophthalmic solution in subjects with mild-to-moderate dry eye syndrome

Next Previous
X
Search
Trial Profile

A phase I/II, double-blind, placebo-controlled study assessing the safety and efficacy of AVX-012 ophthalmic solution in subjects with mild-to-moderate dry eye syndrome

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acoltremon (Primary) ; Acoltremon (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors AVX Pharma

    • Most Recent Events

    • 11 Mar 2021 According to an Aerie Pharmaceuticals media release, data from this study will be presented at the Ophthalmology Innovation Summit Dry Eye Innovation Showcase.
    • 30 Jan 2019 Status changed from recruiting to completed.
    • 28 Sep 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top